Atai Life Sciences and Beckley Psytech Limited announced encouraging Phase 2b trial results and plans to engage the FDA regarding Phase 3 trial design.
2 reports, 0 independent
Updated Jul 9
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Atai Life Sciences and Beckley Psytech Limited announced encouraging Phase 2b trial results and plans to engage the FDA regarding Phase 3 trial design.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Atai Life Sciences
German pharmaceutical company
Nothing else this week.
- FDA
Related events
- Matricelf Ltd. is seeking feedback from the FDA regarding its clinical trial design. The company is currently listed on the Tel Aviv Stock Exchange with plans for a dual listing to support its transition.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Yamo Pharmaceuticals LLC plans to conduct a Phase 3 study in the US, with drug development regulated by the FDA.
- FDA approval enables commercial availability for a product associated with Indianapolis.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet